Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Clinical trials and projected future of liver xenotransplantation.

Fung, J and Rao, A and Starzl, T (1997) Clinical trials and projected future of liver xenotransplantation. World J Surg, 21 (9). 956 - 961. ISSN 0364-2313

[img]
Preview
PDF
Accepted Version
Available under License : See the attached license file.

Download (1MB) | Preview
[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)

Abstract

The trial and error of the pioneering xenotransplant trials over the past three decades has defined the limitation of the species used. Success was tantalizingly close with the chimpanzee, baboon, and other primates. The use of more disparate species has been frustrated by the xenoantibody barrier. Future attempts at clinical xenotransplantation will be hampered by the consideration of the species of animals and the nature of the organs to be transplanted. On one hand, primate donors have the advantage of genetic similarity (and therefore potential compatibility) and less risk of immunologic loss. On the other hand, pig donors are more easily raised, are not sentient animals, and may be less likely to harbor transmissible disease. It is recognized that the success of xenotransplantation may very with different organs. Because it is relatively resistant to antibody-mediated rejection, the liver is the organ for which there is the greatest chance of long-term success. Consideration of using xenotransplants on a temporary basis, or as a "bridge" to permanent human transplantation, may allow clinical trials utilizing hearts or kidney xenografts. Issues on metabolic compatibility and infection risks cannot be accurately determined until routine success in clinical xenotransplantation occurs. Based on a limited experience, the conventional approaches to allotransplantation are unlikely to be successful in xenotransplantation. The avoidance of immediate xenograft destruction by hyperacute rejection, achieved using transgenic animals bearing human complement regulatory proteins or modulating the antigenic target on the donor organ, is the first step to successful xenotransplantation. The ability to achieve tolerance by establishing a state of bone marrow chimerism is the key to overcoming the long-term immunologic insults and avoiding the necessarily high doses of nonspecific immunosuppression that would otherwise be required and associated with a high risk of infections complications. Xenotransplantation faces criticism that is strongly reminiscent of that leveled against human-to-human transplantation during the late 1960s and early 1970s. Yet with persistence, the field of human-to-human transplantation has proved highly successful. This success was the result of a stepwise increase in our understanding of the biology of rejection, improvements in drug management, and experience. It is possible that xenotransplantation may not be universally successful until further technologic advances occur; yet cautions exploration of xenotransplantation appears warranted to identify those areas that require further study.


Share

Citation/Export:
Social Networking:
Share |

Details

Item Type: Article
Status: Published
Creators/Authors:
CreatorsEmailPitt UsernameORCID
Fung, J
Rao, A
Starzl, Ttes11@pitt.eduTES11
Centers: Other Centers, Institutes, or Units > Thomas E. Starzl Transplantation Institute
Date: November 1997
Date Type: Publication
Journal or Publication Title: World J Surg
Volume: 21
Number: 9
Page Range: 956 - 961
Institution: University of Pittsburgh
Refereed: Yes
Uncontrolled Keywords: Animals, Clinical Trials as Topic, Forecasting, Graft Rejection, Humans, Immunosuppression, Liver Transplantation, Transplantation, Heterologous
ISSN: 0364-2313
Funders: NIDDK NIH HHS (R01 DK029961-19)
Other ID: uls-drl:31735062127224, Starzl CV No. 2000
Date Deposited: 08 Apr 2010 17:34
Last Modified: 16 Oct 2017 16:55
URI: http://d-scholarship.pitt.edu/id/eprint/5386

Metrics

Monthly Views for the past 3 years

Plum Analytics


Actions (login required)

View Item View Item